- Home
- JANX
as of 12-05-2025 3:59pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.8B | IPO Year: | 2021 |
| Target Price: | $62.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.51 - $71.71 | Next Earning Date: | 11-06-2025 |
| Revenue: | $10,000,000 | Revenue Growth: | -23.37% |
| Revenue Growth (this year): | -12.73% | Revenue Growth (next year): | -81.03% |
AI-Powered JANX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
Chief Business Officer
Avg Cost/Share
$33.19
Shares
3,333
Total Value
$109,929.10
Owned After
85,607
Chief Business Officer
Avg Cost/Share
$30.06
Shares
16,665
Total Value
$500,986.56
Owned After
85,607
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | JANX | Chief Business Officer | Dec 1, 2025 | Sell | $33.19 | 3,333 | $109,929.10 | 85,607 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Oct 28, 2025 | Sell | $30.06 | 16,665 | $500,986.56 | 85,607 |
Compare JANX vs Leading Stocks
See how JANX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.